Switch theme
Sign up to access all valuation multiples
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
2017
479
LTM Revenue $10.0M
LTM EBITDA -$292M
$285M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Replimune Group has a last 12-month revenue (LTM) of $10.0M and a last 12-month EBITDA of -$292M.
In the most recent fiscal year, Replimune Group achieved revenue of n/a and an EBITDA of -$235M.
Replimune Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Replimune Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $8.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$292M | XXX | -$235M | XXX | XXX | XXX |
| EBITDA Margin | -2903% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$271M | XXX | -$260M | XXX | XXX | XXX |
| EBIT Margin | -2699% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$251M | XXX | -$247M | XXX | XXX | XXX |
| Net Margin | -2495% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Replimune Group's stock price is $9.
Replimune Group has current market cap of $692M, and EV of $285M.
See Replimune Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $285M | $692M | XXX | XXX | XXX | XXX | $-3.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Replimune Group has market cap of $692M and EV of $285M.
Replimune Group's trades at n/a EV/Revenue multiple, and -1.2x EV/EBITDA.
Equity research analysts estimate Replimune Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Replimune Group has a P/E ratio of -2.8x.
See valuation multiples for Replimune Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $692M | XXX | $692M | XXX | XXX | XXX |
| EV (current) | $285M | XXX | $285M | XXX | XXX | XXX |
| EV/Revenue | 28.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.0x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | -1.0x | XXX | -1.1x | XXX | XXX | XXX |
| EV/Gross Profit | 35.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -2.9x | XXX | XXX | XXX |
| EV/FCF | -3.6x | XXX | -1.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialReplimune Group's last 12 month revenue growth is 650%
Replimune Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Replimune Group's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Replimune Group's rule of X is -1279% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Replimune Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 650% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2903% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1279% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Replimune Group acquired XXX companies to date.
Last acquisition by Replimune Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Replimune Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Replimune Group founded? | Replimune Group was founded in 2017. |
| Where is Replimune Group headquartered? | Replimune Group is headquartered in United States of America. |
| How many employees does Replimune Group have? | As of today, Replimune Group has 479 employees. |
| Who is the CEO of Replimune Group? | Replimune Group's CEO is Dr. Sushil Patel, PhD. |
| Is Replimune Group publicy listed? | Yes, Replimune Group is a public company listed on NAS. |
| What is the stock symbol of Replimune Group? | Replimune Group trades under REPL ticker. |
| When did Replimune Group go public? | Replimune Group went public in 2018. |
| Who are competitors of Replimune Group? | Similar companies to Replimune Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Replimune Group? | Replimune Group's current market cap is $692M |
| What is the current revenue of Replimune Group? | Replimune Group's last 12 months revenue is $10.0M. |
| What is the current revenue growth of Replimune Group? | Replimune Group revenue growth (NTM/LTM) is 650%. |
| What is the current EV/Revenue multiple of Replimune Group? | Current revenue multiple of Replimune Group is 28.3x. |
| Is Replimune Group profitable? | Yes, Replimune Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Replimune Group? | Replimune Group's last 12 months EBITDA is -$292M. |
| What is Replimune Group's EBITDA margin? | Replimune Group's last 12 months EBITDA margin is -2903%. |
| What is the current EV/EBITDA multiple of Replimune Group? | Current EBITDA multiple of Replimune Group is -1.0x. |
| What is the current FCF of Replimune Group? | Replimune Group's last 12 months FCF is -$79.7M. |
| What is Replimune Group's FCF margin? | Replimune Group's last 12 months FCF margin is -793%. |
| What is the current EV/FCF multiple of Replimune Group? | Current FCF multiple of Replimune Group is -3.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
